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Abstract
Objective: Left ventricular assist devices (LVADs) are utilized as a bridge to
transplant or as destination therapy for patients with end-stage heart failure.
Although cardiac offloading from these devices rarely leads to complete
remodeling and functional recovery, the use of mesenchymal cells to modulate
heart failure has been explored in recent years due to its intrinsic regenerative
properties. Current methods of evaluating cardiac function have too much
variability, difficulty of access, or require too frequent follow up to create universal
weaning protocols. We hypothesized that the administration of amniotic allograft
liquid matrix (LM) containing amnion-derived mesenchymal stem cells (aMSCs) in
patients with LVADs could improve left ventricular function and be positively
associated with pulsatility.
Methods: Flow cytometry, mass spectroscopy, and enzyme-linked immunoassays
were used to characterize aMSCs and LM that were administered to 9 patients
with LVADs. Results were compared to samples from 7 control patients with
LVADs that did not receive aMSC and LM.
Results: Patients who received aMSCs and LM (n=9) demonstrated a significant
increase in standardized pulsatility at 30 (P = .007), 90 (P = .02), and 180 (P = .05)
days post-implant when compared to control patients who did not receive the
treatment (n=7).
Discussion: We conclude that the use of aMSCs and LM in patients with LVADs
could be a promising treatment strategy, and pulsatility can be a reproducible and
consistent diagnostic metric to evaluate left ventricular function without intra- or
inter-observer variability.
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Introduction
Heart failure (HF) remains a growing epidemic and a leading healthcare cost.
Recent estimates indicate approximately 6.2 million Americans over 20 years of age
have HF, and 42.3% of these patients have a 5-year fatality rate after hospitalization.
This has resulted in an increased economic burden exceeding $30.7 billion.1
Although cardiac transplantation is the optimal therapy for end-stage HF, the
limitation of donor organs has shifted the need, and increased the use, of left
ventricular assist devices (LVADs).
Many regenerative treatment strategies have been attempted to augment and
improve functional recovery in patients with LVADs. The application of
mesenchymal stem cells (MSCs) has demonstrated significant interest in recent
years due to their pluripotency, anti-inflammatory, and immunosuppressive
capabilities. In the PROMETHEUS and TAC-HFT clinical trials, MSC-treated cardiac
tissue improved contractile function and perfusion, and the treatment reduced infarct
size.2,3
The addition of extracellular liquid matrix (LM) containing adhesion and signaling
proteins is hypothesized to improve regeneration and function through improved cell
survival and localization. The feasibility of combining LVAD support and particulate
extracellular matrix (P-ECM) through intramyocardial injections was explored in a
bovine model.4 P-ECM+LVAD treatment provided the most significant increase in
ejection fraction (EF) and reduced cardiac fibrosis 60 days post-treatment.4 A similar
study was performed in patients and revealed delivery of MSCs allowed for
successful weaning 90 days after LVAD implantation compared to the control
group.5 Although these effects have not been consistently reproducible in other
studies, this is perhaps due to inconsistent methods and inter-observer bias in
evaluating cardiac function and recovery.Thus, our goal was to utilize on-board
LVAD diagnostics to identify functional differences between patients administered
with amniotic MSC (aMSCs) and LM at the time of LVAD implantation compared to
control patients (LVAD only).
A universal and reproducible marker of left ventricular (LV) contractility is needed to
determine the patient’s response to therapeutic treatments as current methods of
determining LV function are prone to intra- and inter-observer variability, are too
expensive, or require frequent follow up.7 Pulsatility is the difference between enddiastolic flow from the peak systolic flow during a single cardiac cycle and indirectly
measures contractility. As contractility increases, end-systolic volume decreases,
thereby increasing stroke volume. Our group has previously used an in vitro model
with a Total Artificial Heart (Syncardia Systems, Inc.) and Donovan Mock Circulation
System to accurately correlate pulsatility with cardiac contractility through the
variation of preload, afterload, and LV pumping force.6 Therefore, we retrospectively
studied 16 patients who underwent an LVAD implantation to validate pulsatility as a
marker of improved cardiac function with myocardial aMSCs+LM treatment.
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Methods
Study Design
Internal review board approval was attained for this investigation (#1507990305).
Waiver of informed consent was attained to gather information and analyze samples
from patients, and no patient’s identifiers were used or recorded to protect privacy.
HVAD serial numbers and implant dates were used during data collection for
analysis.
This single-center, retrospective study included patients who underwent a
Heartware Ventricular Assist Device (HVAD, Medtronic) implantation as a bridge to
cardiac transplant between 2013-2015. Patients were placed in two groups:
Controls (HVAD only), and Treatment (patients received aMSC+LM with HVAD
placement at time of chest closure). Every patient who consented to receiving
aMSCs+LM (n=9) at the time of HVAD implant received the therapy. Patients who
received their HVAD prior to availability of aMSCs+LM (n=7) or did not consent to
receiving the additional therapy were placed in the control group.
The treatment (1.2 million aMSCs+LM, 1ml) was delivered via a 22G needle into the
LV myocardium through the LV anterior, inferior, and lateral wall. Additionally, the
aMSCs+LM mixture was injected off-pump (2.4 million, 2ml mixed with 5ml normal
saline) into the right atrium via the right atrial appendage with a 22G needle, steadily
over 5 minutes. The aMSCs+LM were derived from human birth tissue donated
under informed consent following Cesarean sections. Allografts were processed and
packaged at an FDA registered and AATB accredited facility in accordance with
Current Good Manufacturing Practice standards.

Flow Cytometry Analysis
Flow cytometric analysis of the aMSCs+LM was performed to identify the cell
phenotypes and characterize surface antigen markers including CD90, CD44,
CD105, and CD73. Data acquisition and analysis used the 488 nm, 532 nm, and
640 nm laser lines on a BD™ LSR II flow cytometer with FACSDiva™ software (BD
Biosciences). Spectral compensation was adjusted using a cell population with a
single staining and an unstained control.

Characterization of Membrane and Flow Proteins
Lysates of aMSCs membrane were prepared and underwent SDS-PAGE. After
staining with Coomassie Blue, sections were excised, digested, and analyzed by a
Velos™ Orbitrap mass spectrometer (Thermo Scientific) after in-line fractionation by
a C18 column using Proxeon liquid chromatography. The same method was used
to measure protein concentration from the aMSCs+LM.
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Acquisition of Log Files
The log files from the HVAD devices were obtained while caring for the patient. Once
steady-state was achieved in device variability following HVAD implant (~5-10 days
post-implant), a baseline log file data was collected and the exported log files were
analyzed in STATA (StatCorp, LLC) and MATLAB (MathWorks). Parameters that
were evaluated included the following: time, speed (RPM), average flow values
recorded (mLPM), minimum flow values recorded (mLPM), and pulsatility (mLPM).
Pulsatility was calculated by a device algorithm that records the differential between
peak systolic flow velocity and minimum diastolic flow velocity over a 3-second
window every 15 minutes (Figure 1); this method has been validated in another
study.8
Log File Pulsatility (L/min) = HVAD Estimated Flow max – HVAD Estimated Flow min

Figure 1. Pulsatility is the difference between the peak systolic and end-diastolic
flow velocities during a single cardiac cycle. Data shown was acquired from a
Transonic Flow Meter during modeling with the Donovan Mock Circulation loop,
Total Artificial Heart (Syncardia Systsems, Inc), and Heartware Ventricular Assist
Device (Medtronic).

Echocardiography
Echocardiograms were obtained as part of clinical care and interpreted following
standard of care protocols.9 EF was measured and verified by two cardiologists to
limit inter-observer bias. Echocardiograms were not available for all patients at every
time point. Reported EF values were standardized to baseline EF.
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Statistical Methods
Baseline patient characteristic differences were tested using a Fisher’s exact test.
The standardized pulsatility (SP) for each patient was calculated by using the ratio
of pulsatility to baseline pulsatility. We used data from the device log files and the
entirety of the pulsatility data within each 5-day window. Differences between control
and treatment groups, with respect to SP, were analyzed using a Mann-Whitney
nonparametric test with aMSCs+LM administration as the independent variable.

Results
Clinical Characteristics
Baseline characteristics of the control and treated patients were similar (Table 1). At
the time of HVAD implantation, 16 patients were screened for therapy. The majority
(6/7) of the control patients received cardiopulmonary bypass support during their
LVAD implantations, as only one patient was implanted off-pump. However, about
half (5/9) of the aMSCs+LM patients patients received cardiopulmonary bypass
support, and the four other patients were off-pump. There was no significant
difference in hospitalization times (P = .7), bypass times (P = .07), sex (P = .3), renal
failure (P = .3), diabetes (P = 1.0), hypertension (P = .6), or previous cardiac
surgeries (P = .6). There were no significant differences in medications at baseline,
3-, or 6-months post-LVAD implantation (Supplementary Table A). Similarly, no
significant differences in mean arterial pressure (MAP) was found between the
groups at any point (Supplementary Table B). Of note, in the treatment group
(aMSCs + LM), 6 patients had concomitant procedures (2 tricuspid valves, 1 aortic
valve, 2 left atrial appendage ligation, and 1 left ventricular vryoablation) while the
control group did not have any.
Table 1. Demographics and Clinical Characteristics of Study Population.
Data is presented as median (interquartile range) or number (frequency).
Characteristic

aMSCs+LM (n=9)

LVAD only (n=7)

58.0 (50.0 – 64.0)

59.0 (50.0 -66.0)

Male (%)

8 (88.9%)

4 (57.1%)

Renal Failure

4 (44.4%)

1 (14.3%)

Diabetes

3 (33.3%)

3 (42.9%)

Hypertension

6 (66.7%)

3 (42.9%)

Previous Cardiac Surgery

6 (66.7%)

4 (57.1%)

5/4

5/2

32.0 (21.0-59.0)

30.0 (19.0-78.5)

108.0 (107.0-109.0)

98.0 (73.0-117.0)

Age (years)

Mini-thoracotomy/
Full sternotomy
Hospitalization (days)
Bypass Time (mins)
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Pulsatility
There was no statistically significant difference in pulsatility between the aMSCs+LM
and control groups at baseline. Over time, the aMSCs+LM group did demonstrate
significant increases in pulsatility, whereas the control group did not (Figure 2).
Using a Wilcoxon rank-sum test and normalizing pulsatility to baseline, the
aMSCs+LM group demonstrated significant increases in pulsatility at 30- (P = .007),
90- (P = .02), and 180- (P = .05) days post-LVAD implantation when compared to
the control group (Table 2).

Figure 2. Standardized pulsatility of treatment and control patients from Day 5 to
Day 180 after implantation of left ventricular assist device. Significant differences in
pulsatility were found with the treatment group at 30 (P = .007), 90 (P = .02), and
180 (P = .05) days after implantation.

Echocardiography
At baseline, five (55.5%) from the aMSCs+LM group and seven LVAD only patients
had echocardiograms. Subsequent echocardiograms were limited due to lack of
follow-up, and three patients received a heart transplant within the follow-up period.
There was a non-significant trend toward an increased normalized EF and left
ventricular inner diameter (LVID) in the aMSCs+LM patients when compared to the
control group (Figure 3).

Adverse Events
No adverse events related to device implantation or aMSC+LM administration
including acute device failure, thrombosis, immune reactions, stroke, or
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anaphylaxis were reported. There were no device replacements or device-related
deaths in either group.
Additionally, the therapy’s effects on anti-HLA antibody presence (Panel Reactive
Antibody, PRA) were retrospectively analyzed in these patients before and
periodically after aMSC+LM injection. Baseline and postoperative class I and II
PRA screenings were analyzed, along with peri- and postoperative blood product
administration for each patient. Compared to baseline values, all patients’
postoperative HLA sensitization either remained the same or decreased.
Table 2. Standardized pulsatility from baseline to 180 days after LVAD
implantation is presented alongside significance comparisons between groups
aMSCs+LM

LVAD only

Days

P-value
N

SP

SD

N

SP

SD

5-10

9

1.000

0

7

1.000

0

N.S.

15-20

8

1.380

0.517

7

1.014

0.101

0.0270

25-30

8

1.491

0.508

7

1.014

0.126

0.0070

35-40

7

1.516

0.544

6

1.031

0.167

0.0111

45-50

7

1.384

0.607

6

1.016

0.115

0.0688

55-60

8

1.295

0.454

5

0.958

0.085

0.0637

65-70

7

1.380

0.554

5

0.939

0.193

0.1717

75-80

5

1.549

0.628

5

0.905

0.167

0.1230

85-90

6

1.540

0.449

6

1.005

0.198

0.0206

95-100

6

1.358

0.488

6

1.064

0.151

0.0660

105-110

5

1.078

0.222

6

1.094

0.156

0.3961

115-120

5

1.106

0.272

3

1.029

0.211

0.5000

125-130

2

1.156

0.463

2

0.928

0.129

0.5000

135-140

3

1.506

0.492

2

0.947

0.088

0.2000

145-150

6

1.151

0.442

3

1.091

0.187

0.3571

155-160

6

1.302

0.407

2

1.022

0.366

0.2143

165-170

5

1.345

0.409

4

0.925

0.218

0.0952

175-180

3

1.479

0.294

3

0.830

0.136

0.0500

* N, number of patients; SP, standardized pulsatility; SD, standard deviation
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Figure 3. Comparison of normalized ejection fraction (EF, %) and left venricular
internal diameter (LVID, cm) to baseline of the mesenchymal stem cell/liquid
matrix (aMSC) group and Control group (left ventricular assist device only)
between baseline and six months. The treatment group demonstrated a trend
toward increased normalized EF and LVID over the 6-month time period.

Discussion
Pulsatility is a useful, indirect measure of contractile function in patients with an
implanted LVAD. Prior reports of stem cell administration in patients show
improvements in EF and infarct size, and stem cell therapy shows the potential for
VAD weaning and explantation.5 Yet, these studies do not have enough
consistency to support widespread adoption. Though prior studies found a positive
trend in VAD weaning success with stem cell therapy, they did not demonstrate
significant improvements.5 This may be attributed to the administration of
mesenchymal precursor cells rather than the mature heterogeneous mixture of
aMSCs+LM presented here. Other studies use the primary endpoints of EF or
infarct size to determine cardiac status.2,3 These diagnostic methods are prone to
intra-observer and inter-observer variability.7 Additionally, echocardiograms are
taken at discrete time points where the patient’s results may not reflect their longterm status. Hence, it is difficult to compare the published studies. Pulsatility offers
the advantage of being an objective, reproducible, and consistent method through
device diagnostics while providing continuous data, unlike discrete data gathered
from other HF diagnostics. This analysis method can be used across different
therapy types and implanting centers to create a universal weaning protocol.
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This retrospective analysis found that pulsatility, a derivative of stroke volume,
increased in patients with advanced HF receiving aMSCs+LM therapy during
LVAD implantation.Patients who were treated with aMSCs+LM demonstrated
significant increases in pulsatility from baseline values compared to control
patients at 30, 90, and 180 days postoperatively. Importantly, the mean
standardized pulsatility for the aMSCs+LM group did not fall below 1.00,
suggesting contractile function only improved during the study. In comparison, the
control (LVAD only) group did not demonstrate improved pulsatility; many patients
(4/7) demonstrated reductions in pulsatility over time after implantation. We found
no significant differences in MAP between the groups at any point. Afterload was
directly proportional to MAP, and our group has previously demonstrated that if
afterload remains constant, an increase in pulsatility will only occur with improved
cardiac contractility and increased preload.6,10 This suggests all patients
experiencing an improvement in pulsatility also improved their stroke volume and
stroke work.
Some hearts may be unable to restore contractile function or remodel even in
unloaded conditions. The observed reduction in pulsatility contradicts current
literature that suggests unloading the LV increases contractility for patients with
end-stage HF.11 Similarly, the aMSCs+LM group demonstrated a larger positive
trend in EF and LVID compared to control. In contrast, EF in the control group
returned to baseline within six months. These data support the hypothesis that use
of aMSCs+LM improves heart function in contrast to LVAD alone. These data also
correspond with the data attained from an in vitro model that showed anticipated
pulsatility increase with improved cardiac contractility.6
Characterization of aMSCs through flow cytometry confirmed the presence of
surface antigens CD73+, CD90+, and CD105+, which is consistent with aMSC
lineage (Figure 4, Supplemental Table C). The aMSCs+LM therapy also contained
markers that previous studies have demonstrated to have roles in cell survival and
proliferation in cardiac models (Supplementary Table D).12,13 Others proteins
notable in the aMSCs+LM therapy included collagen VI and fibronectin, which
have shown an increase in endogenous stem cell self-renewal, muscle
regeneration, and activation of satellite cells (Supplementary Table D).14,15
A substantial portion of the proteins, cytokines, gene expression, and growth
factors identified within the aMSCs+LM samples aid in cell-cell interactions,
cellular retention, growth proliferation, extracellular matrix integrity, cell migration,
angiogenesis, oxidative homeostasis, and cardiomyocyte differentiation. This may
explain why patients receiving aMSCs+LM therapy demonstrated significant
increases in pulsatility and improved EF compared to LVAD only patients.
Improvement of pulsatility in the aMSCs+LM group may be attributed to the
administered allograft's immunomodulatory and paracrine factors. Additionally,
proteins that synergistically exhibit antimicrobial effects, such as inducible gene-H3
(IG-H3) and natriuretic peptides B precursor (NPPB), are in aMSCs+LM
(Supplementary Figure A). This may assist in stem cell retention by inducing an
anti-inflammatory environment, particularly in patients supported by VADs.
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Figure 4. Histogram of flow cytometric analysis of amnion-derived mesynchymal
stem cells confirmting the presence of CD44+, CD73+, CD90+, and CD105+ cells.
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Moreover, a high concentration of NPPB is suggestive of heart failure and
functions as a paracrine antifibrotic factor in the heart.
Though the results of this study are promising, it has limitations. Due to the nature
of a retrospective study, the groups were non-randomized. The data collection
decreased over time due to patients lost to follow up, which limited data analysis
and statistical power at later time points. The HVAD data retention was limited to
only 31 days due to device specifications. Therefore, there were gaps in collected
pulsatility data from patients who were not subsequently evaluated. So while
results from this study suggest cardiac status improvement with aMSCs+LM
therapy, a larger, prospective study would be necessary to draw meaningful
conclusions of the therapy efficacy on a larger scale.
In conclusion, the findings demonstrate the administration of aMSCs+LM improved
cardiac function in this limited cohort of patients, but a large-scale study is needed
to determine if widespread improvements are observed. The HVAD diagnostic
metric, pulsatility, was demonstrated to be a meaningful measure of cardiac
contractility in patients, consistent with our group’s prior findings from an in vitro
model. This suggests pulsatility could be used as an objective endpoint in
determining when a patient has recovered sufficiently to warrant HVAD explant,
independent of the therapy used to restore LV contractility.
With the discontinuation of the HVAD, it would be beneficial to explore the addition
of the pulsatility index in similar HF devices. The results from this initial study
provide support for a prospective study to determine widespread response and to
create an LVAD weaning protocol dependent on improvements in pulsatility.
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